LA JOLLA, Calif., June 26 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc. (OTC Bulletin Board: DSKA.OB) ("Duska" or the "Company") announced today that its company information is available via Standard & Poor's Corporation Records Listing Program. As part of the program, a full description of Duska Therapeutics is published in the Daily News section of Standard Corporation Records, a recognized securities manual for secondary trading in approximately 38 states under the Blue Sky Laws. Standard Corporation Records is available in print, on CD-ROM, and via the Web at http://www.netadvantage.standardandpoors.com as well as through numerous electronic vendors.
The Duska Therapeutics corporate information now available through the Records Listing Program includes an in-depth description of the Company's business operations, share price, dividend history, shares outstanding, company's financial position, earnings, and full income statement and balance sheet.
Earlier this month Duska Therapeutics announced it has been granted an exclusive worldwide license from Duke University and Johns Hopkins University to develop and commercialize their rights to a portfolio of investigational cardiovascular drugs designed to correct nitric oxide and redox disequilibrium in the failing heart and cardiovascular system. The lead candidate is expected to enter Phase II clinical trials later this year.
About Duska Therapeutics, Inc.
Duska Therapeutics, Inc., in La Jolla, California, is a biotechnology company focused on the development of medical products based on adenosine triphosphate and nitric oxide. Duska owns or has exclusive licensing rights to proprietary medical products that are in various stages of development for the treatment and diagnosis of certain cardiac arrhythmias, treatment of heart failure, treatment of chronic obstructive pulmonary disorder, and improvement of sperm motility. For more information, visit http://www.duskatherapeutics.com.
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. The forward-looking statements are based on current expectations, estimates and projections made by management. Duska intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," or variations of such words are intended to identify such forward-looking statements. All statements in this release regarding the future outlook related to Duska are forward-looking statements such as the lead candidate is expected to enter Phase II clinical trials later this year. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Additional uncertainties and risks are described in Duska's most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-QSB and any current reports on Form 8-K filed since the date of the last Form 10-KSB. Copies of these filings are available through the SEC website at http://www.sec.gov. All forward-looking statements are based upon information available to Duska on the date hereof. Duska undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.
|SOURCE Duska Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved